Jennie Shuman, Consultant, Author at EverGlade Consulting

Jennie Shuman, Consultant

Jennie Shuman, EverGlade Consultant

BARDA Issues New RPP to Advance Smart Manufacturing for Antibodies

Driving Innovation in Antibody Manufacturing The Biomedical Advanced Research and Development Authority (BARDA) has launched a new Request for Project Proposals (RPP) aimed at transforming the speed, efficiency, and resilience of antibody (Ab) production. Issued under the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), the initiative seeks to integrate advanced manufacturing technologies into Ab production systems to […]

BARDA Issues New RPP to Advance Smart Manufacturing for Antibodies Read More »

DTRA–MTEC Pre-Announcement for Biodefense Readiness RPP

MTEC-25-DTRA Pre-Announcement: Advancing Biodefense Readiness The Medical Technology Enterprise Consortium (MTEC), in support of the Defense Threat Reduction Agency (DTRA), has issued a pre-announcement for an upcoming Request for Project Proposals (RPP). This RPP will be aimed at accelerating medical countermeasures (MCMs) and fieldable biosurveillance technologies across the Chemical and Biological Defense Program. In brief,

DTRA–MTEC Pre-Announcement for Biodefense Readiness RPP Read More »

Biothreat Pathogens

BARDA Launches RFP for vaccines targeting Marburg virus (MARV) and Sudan ebolavirus (SUDV)

BARDA RFP – Marburg Virus and Sudan Ebolavirus Vaccine Licensure and Procurement On July 12, 2025, the Biomedical Advanced Research and Development Authority (BARDA) issued Request for Proposals (RFP) #75A50125R00006. This RFP seeks proposals for the advanced development, FDA licensure, and procurement of vaccines targeting Marburg virus (MARV) and Sudan ebolavirus (SUDV). With recent outbreaks

BARDA Launches RFP for vaccines targeting Marburg virus (MARV) and Sudan ebolavirus (SUDV) Read More »

Close up of blue antibiotic capsules

BARDA Launches New RFP to Bolster Antibiotic Stockpiles Against Drug-Resistant and Biothreat Pathogens

Request for Proposals (RFP) for Antibiotic for Treatment of Bacterial Pneumonia or Bloodstream Infections Bolstering Biodefense with Advanced Antibiotics: BARDA’s Strategic Move As the threat of antibiotic-resistant infections intensifies, the U.S. Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA), has issued a pivotal solicitation under Project BioShield

BARDA Launches New RFP to Bolster Antibiotic Stockpiles Against Drug-Resistant and Biothreat Pathogens Read More »

Blue digitally distorted brain illustration

ARPA-H Announces the Functional Repair of Neocortical Tissue (FRONT) Program

Functional Repair of Neocortical Tissue (FRONT) Health Science Futures (HSF) Innovative Solutions Opening (ISO) ARPA-H-SOL-25-120 July 10, 2025 Restoring the Damaged Brain: ARPA-H’s FRONT Program Targets Functional Neocortical Repair The Advanced Research Projects Agency for Health (ARPA-H) has announced an ambitious new program under its Health Science Futures (HSF) office: the Functional Repair of Neocortical

ARPA-H Announces the Functional Repair of Neocortical Tissue (FRONT) Program Read More »

Cortisol molecule

DARPA’s CoasterChase Initiative

CoasterChase – BIOLOGICAL TECHNOLOGIES OFFICE – HR001125S0014 Targeting Stress from the Inside Out: DARPA’s CoasterChase Initiative The Defense Advanced Research Projects Agency (DARPA) continues to push the boundaries of biomedical technology with the release of its latest Broad Agency Announcement (BAA), HR001125S0014, titled CoasterChase. Issued by DARPA’s Biological Technologies Office (BTO), this program seeks to

DARPA’s CoasterChase Initiative Read More »

enzymatic debridement product

BARDAs Strategic Investment in Enzymatic Debridement Products

Advancing Burn Care Preparedness: BARDA’s Strategic Investment in Enzymatic Debridement Products In its ongoing mission to strengthen the nation’s biodefense and emergency response infrastructure, the Biomedical Advanced Research and Development Authority (BARDA), an office within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services, has released a

BARDAs Strategic Investment in Enzymatic Debridement Products Read More »

Transparent ampules on a blue background

BARDA’s Call to Action Antibiotics for Treatment of Bacterial Pneumonia or Bloodstream Infections

Combating Resistant Infections: BARDA’s Push for Advanced Antibiotics The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), has released a pre-solicitation notice aimed at identifying qualified vendors to support the late-stage development, procurement, and stockpiling of antibiotics for critical public health threats. Targeted programs include

BARDA’s Call to Action Antibiotics for Treatment of Bacterial Pneumonia or Bloodstream Infections Read More »

Vaccine Development

BARDA’s Call to Action on Marburg and Sudan Virus Vaccines

Preparing for the Next Biological Threat: BARDA’s Vaccine Initiative for MARV and SUDV The Biomedical Advanced Research and Development Authority (BARDA), operating under the U.S. Department of Health and Human Services (HHS), has issued a pre-solicitation notice signaling its intent to launch a major Request for Proposal (RFP) later this year. This effort, managed by

BARDA’s Call to Action on Marburg and Sudan Virus Vaccines Read More »

3d rendered image of highly pathogenic avian influenza

MCDC Announces “Increased Micro Sampling to Monitor Immunological Response” RPP

The Joint Science and Technology Office (JSTO) within the Defense Threat Reduction Agency (DTRA), has issued a new Request for Prototype Proposals (RPP) through the Medical CBRN Defense Consortium (MCDC). “Increased Micro Sampling to Monitor Immunological Response” (IMMIR) seeks to improve our ability to monitor immune responses to vaccination, which is critical for accelerating vaccine

MCDC Announces “Increased Micro Sampling to Monitor Immunological Response” RPP Read More »

digital rendering of antigens

MCDC Releases “Defined Rapid Antigen Identification and Immunogenic Characterization” RPP

The U.S. Department of Defense (DoD), through the Joint Science and Technology Office (JSTO) Defense Threat Reduction Agency (DTRA), has released a new Request for Prototype Proposals (RPP-25-07) under the Medical CBRN Defense Consortium (MCDC). This Request for Project Proposals, titled “Defined Rapid Antigen Identification and Immunogenic Characterization” (DRAIIC), aims to increase protection against infectious

MCDC Releases “Defined Rapid Antigen Identification and Immunogenic Characterization” RPP Read More »

Medicine production on conveyor belt

IBMSC RISE OTA Consortium RFI

Request for Information – IBMSC Resilient Industry and Supply Chain Enterprise (RISE) OTA Consortium In June 2025, the U.S. Department of Health and Human Services (HHS) issued a Request for Information (RFI) through the Administration for Strategic Preparedness and Response’s (ASPR) Center for Industrial Base Management and Supply Chain (IBMSC). This RFI invites feedback from

IBMSC RISE OTA Consortium RFI Read More »

Scroll to Top